Public-domain · open source
OpenJurist
← 238 FSUPP2D 191 - Purepac Pharmaceutical Co. v. Thompson

Purepac Pharmaceutical Co. v. Thompson’s Empirical Analysis

2002

Citation profile

16
cited by 16 later decisions
1
states following
November 2020
most recently cited

4 federal appellate · 6 district · 1 state decisions

How this case has been cited

Cited by 16 later decisions — most recently November 2020

4 federal appellate · 6 district · 1 state decisions

110200220102020decided

Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.

Relationships

Applies 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act) · 35 U.S.C. § 271 · 5 U.S.C. § 701

Relies on Motor Vehicle Manufacturers Association of United States Inc v. State Farm Mutual Automobile Insurance Company Consumer Alert · Bowman Transportation, Inc. v. Arkansas-Best Freight System, Inc. · Eli Lilly & Co. v. Medtronic, Inc. · Mova Pharmaceutical Corp. v. Shalala · American Bioscience, Inc. v. Thompson

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 16 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “[A]t oral argument, the agency stated that it has not taken a definitive position as to whether equitable considerations might ultimately persuade it to allow two applicants to submit a certification and a statement, respectively, with respect to the same patent. As such, the FDA has not decided whether it could, or would, approve TorPharm’s application with a paragraph IV certification to the ’479 patent even if the Court were to direct the agency to accept Purepac’s application with a section viii statement. Because the agency ha,s not done so, and because Purepac has not demonstrated that such a result is barred by the terms of the statute or precluded by existing FDA regulations, the Court will leave this delicate question for the agency to resolve in the first instance.”
    2 later decisions quote this exact passage · from the majority
  2. “the FDA may [thus] approve a section viii application immediately, making it an attractive route for generic manufacturers, even though a section viii statement does not entitle a successful applicant to the 180-day period of exclusivity bestowed on paragraph IV applicants.”
    1 later decision quote this exact passage · from the majority
  3. “[t]he agency ... tried to construct a legal fiction about the scope of the '479 patent and to use that construct to ignore crucial facts (i.e. what Warner-Lambert actually said) about that patent's reach, facts that reveal the ultimate falsity of the agency's fiction.”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.